Health Condition 1: I26-I28- Pulmonary heart disease and diseases of pulmonary circulation
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Sponsors
Dr Pallapothu Devee Sujan
Eligibility
Inclusion criteria
Inclusion criteria: Patients of either sex aged more than 13 years who are newly diagnosed with Pulmonary Hypertension Patients of either sex aged more than 13 years currently on treatment for Pulmonary Hypertension for last 6 months Patients willing to participate and give consent.
Exclusion criteria
Exclusion criteria: Patients below 13 years of age Patients with pre-existing right-heart pathology History of recent surgery (within the last 6 months) History of previous myocardial infarction (MI) Pregnant women Patients currently taking vitamin supplements History of recent infection or sepsis Patients taking antioxidants, glibenclamide, or nicorandil Pregnancy, lactation, or intention to become pregnant during the treatment period Individuals who are unable to give consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The Primary outcome measure of the current study is to measure NOX-1, NOX-4 and ET-1 which is used to correlate with Pulmonary Hypertension. Multiple pre clinical studies and human invitro studies have reported the role of Nox enzymes in pathology and progression of Pulmonary Hypertension. Till date no clinical study have been done measuring Nox levels, endothelin-1, oxidative stress markers and vitamin-D in serum and correlating it with Pulmonary hypertensionTimepoint: Single point Baseline will be taken | — |
Secondary
| Measure | Time frame |
|---|---|
| nilTimepoint: | — |
Countries
India
Contacts
Public ContactDevee Sujan
AIIMS, New Delhi
Outcome results
None listed